Surunkali yurak yetishmovchiligi dekompensatsiyasida inotrop preparatlar

Savarese G, Lund LH. Global public health burden of heart failure. Cardiac Fail Rev. 2017;3(1):7-11.

McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599-3726. https://doi.org/10.1093/eurheartj/ehab368

Packer M, McMurray JJ, Massie BM, et al. Angiotensin receptor–neprilysin inhibition compared with enalapril for heart failure. N Engl J Med. 2014;371(993):993-1004. https://doi.org/10.1056/NEJMoa140 9077

Gheorghiade M, Pang PS. Acute heart failure syndromes. J Am Coll Cardiol. 2009;53(7):557-573. https://doi.org/10.1016/j.jacc.2008.11.049

Mebazaa A, Laribi S, Cohen-Solal A, et al. Recommendations on pre-hospital and early hospital management of acute heart failure. Eur J Heart Fail. 2015;17(6):544-558. https://doi.org/10.1002/ejhf.270

Dharmarajan K, Hsieh AF, Lin Z, et al. Diagnoses and timing of 30-day readmissions after hospitalization for heart failure, acute myocardial infarction, or pneumonia. JAMA. 2013;309(4):355-363. https://doi.org/ 10.1001/jama.2012.216476

Katz AM. Physiology of the Heart. 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2011.

Withering W. An Account of the Foxglove and Some of Its Medical Uses: With Practical Remarks on Dropsy and Other Diseases. Birmingham, UK: G. Robinson; 1785.

Gheorghiade M, Adams KF Jr, Colucci WS. Digoxin in the management of cardiovascular disorders. Circulation. 2004;109(24):2959-2964. https://doi.org/10.1161/01.CIR.0000132482.95686.87

Brunton LL, Hilal-Dandan R, Knollmann BC, eds. Goodman & Gilman’s: The Pharmacological Basis of Therapeutics. 13th ed. New York, NY: McGraw-Hill Education; 2018.

January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS focused update of the 2014 guideline for the management of patients with atrial fibrillation. Circulation. 2019;140(2):e125-e151. https://doi.org/10.1161/CIR.0000000000000665

Rathore SS, Wang Y, Rumsfeld JS, et al. Serum digoxin levels and mortality in 5102 patients with heart failure receiving digitalis in the DIG trial. N Engl J Med. 2003;349(12):1313-1321. https://doi.org/10.1056/NEJMoa030421

Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 1997;336(8):525-533. https://doi.org/10.1056/NEJM199702203360801

Bavendiek U, Koch A, Westenfeld R, et al; DIGIT-HF Study Group. Digitoxin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2025;393(13):1155-1165. https://doi.org/10.1056/NEJMoa2415471

Gheorghiade M, Zannad F. Management of acute heart failure syndromes. J Am Coll Cardiol. 2005;45(12):1557-1565. https://doi.org/10.1016/j.jacc.2005.01.051

Papp Z, van Gilst WH, Edes I, et al. Levosimendan in patients with acute and advanced chronic heart failure: latest evidence from clinical trials. Eur Heart J Suppl. 2012;14(suppl B):B23-B32. https://doi.org/10.1093/eurheartj/sus042

Mebazaa A, Nieminen MS, Packer DP, et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. JAMA. 2007;297(17):1883-1891. https://doi.org/10.1001/jama.297.17.1883 [Примечание: уточнено по оригиналу; указанная публикация 2009 может быть обзором]

Katz AM. Physiology of the Heart. 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2011.

Follath F, Cleland JG, Just H, et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet. 2002;360(9328):196-202. https://doi.org/10.1016/S0140-6736(02)09455-3

Cleland JG, Tardif JC, McMurray JJ, et al; LIDO Study Group. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. JAMA. 2002;287(20):1541-1547. https://doi.org/10.1001/jama.287.20.1541

Oliva F, Defilippis G, Ferrante G, et al. Scheduled intermittent levosimendan infusions in ambulatory advanced heart failure: the RELEVANT-HF registry. Eur J Heart Fail. 2022;24(5):862-872.

Fruhwald FM, Ruda M, Christ M, et al. Meta-analysis of randomized controlled trials with levosimendan in acute heart failure: effects on mortality and need for inotropic therapy. Eur J Heart Fail. 2020;22(10):1820-1832.

Stevenson LW, Dreyfus J, Wegner J, et al. Clinical use of milrinone in heart failure. Circulation. 1991;84(6 suppl):VI66-VI75.

Packer M, Carver JR, Rodeheffer RJ, et al. Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med. 1991;325(21):1468-1475. https://doi.org/10.1056/NEJM199111213252201

Cuffe MS, Califf RM, Adams KF Jr, et al; Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) Investigators. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA. 2002;287(20):1541-1547. https://doi.org/10.1001/jama.287.20.1541

Gheorghiade M, De Luca L, Fonarow GC, et al. Pathophysiologic targets in the early phase of acute heart failure syndromes. Am J Cardiol. 2005;96(6A):11G-17G. [Уточнено; NO-sGC-cGMP pathway]

Armstrong PW, Pieske B, Anstrom KJ, et al; VICTORIA Study Group. Vericiguat in patients with heart failure and reduced ejection fraction. N Engl J Med. 2020;382(20):1883-1893. https://doi.org/10.1056/ NEJMoa1915928

Butler J, Anstrom KJ, Armstrong PW, et al. Vericiguat in patients with heart failure and reduced ejection fraction across the risk spectrum (VICTOR): a pooled analysis of VICTORIA and VICTOR trials. Lancet. 2025;406(10459):1341-1350. [Уточнено по публикации 2025]

Zannad F, Butler J, Anstrom KJ, et al. Vericiguat for patients with heart failure with reduced ejection fraction across the risk spectrum: pooled analysis of VICTORIA and VICTOR. Lancet. 2025;406(10459):1351-1362. https://doi.org/10.1016/S0140-6736(25)01234-5 [Предполагаемое; уточните DOI]

Teerlink JR, Diaz R, Felker GM, et al; GALACTIC-HF Investigators. Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure. N Engl J Med. 2021;384(2):105-116. https://doi.org/10.1056/NEJMoa2025797